propranolol has been researched along with Bronchial Hyperreactivity in 21 studies
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.
Bronchial Hyperreactivity: Tendency of the smooth muscle of the tracheobronchial tree to contract more intensely in response to a given stimulus than it does in the response seen in normal individuals. This condition is present in virtually all symptomatic patients with asthma. The most prominent manifestation of this smooth muscle contraction is a decrease in airway caliber that can be readily measured in the pulmonary function laboratory.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The β-blocker propranolol was discovered to be highly effective for the treatment of infantile hemangiomas (IHs), since 2008." | 7.80 | Adverse effects of propranolol treatment for infantile hemangiomas in China. ( Babajee, K; Chen, X; Hu, X; Jian, D; Li, J; Su, J; Xie, H, 2014) |
| "This study investigates the role of adrenal-derived catecholamines and corticosterone on the inhibition by rolipram, a phosphodiesterase (PDE)-4 inhibitor, of pulmonary eosinophilia and airway hyperresponsiveness (AHR) in allergic mice." | 7.70 | Inhibition of pulmonary eosinophilia and airway hyperresponsiveness in allergic mice by rolipram: involvement of endogenously released corticosterone and catecholamines. ( Chapman, RW; Crawley, Y; Kreutner, W; Kung, TT; Luo, B; Young, S, 2000) |
| "Inhaled propranolol (P) was administered to a population which included asthmatic children (30 subjects) and adults (43 subjects): 1) to investigate the determinants of induced bronchial response; 2) to examine the relationship with treatment requirements; 3) to determine the relationship with responsiveness to methacholine (M) and ultrasonically nebulized distilled water (UNDW) (50 subjects); and 4) to establish the short-term repeatability of bronchial response to propranolol compared with methacholine (22 subjects)." | 7.68 | Bronchial responsiveness to inhaled propranolol in asthmatic children and adults. ( Chetta, A; Foresi, A; Mastropasqua, B; Moretti, D; Olivieri, D; Pelucchi, A, 1993) |
| "Propranolol appears to be an effective treatment option for IH even in the nonproliferative phase and after the first year of life." | 5.37 | Adverse effects of propranolol when used in the treatment of hemangiomas: a case series of 28 infants. ( Breugem, CC; Breur, JMPJ; de Graaf, M; Pasmans, SGMA; Raphaël, MF; Vos, M, 2011) |
| "To determine the risk of developing acute bronchial spasm and bronchial hyperreactivity in healthy subjects after inhaling hydrochloric acid aerosol of different pH, since various characteristics of inhaled aerosol, particularly its acidity, contribute to the reduction in lung function in patients with a pre-existing disease." | 5.11 | Risk of acute bronchospasm and bronchial hyperreactivity from inhaled acid aerosol in healthy subjects: randomized, double-blind controlled trial. ( Mirić, M; Plavec, D, 2004) |
| "The β-blocker propranolol was discovered to be highly effective for the treatment of infantile hemangiomas (IHs), since 2008." | 3.80 | Adverse effects of propranolol treatment for infantile hemangiomas in China. ( Babajee, K; Chen, X; Hu, X; Jian, D; Li, J; Su, J; Xie, H, 2014) |
| "This study investigates the role of adrenal-derived catecholamines and corticosterone on the inhibition by rolipram, a phosphodiesterase (PDE)-4 inhibitor, of pulmonary eosinophilia and airway hyperresponsiveness (AHR) in allergic mice." | 3.70 | Inhibition of pulmonary eosinophilia and airway hyperresponsiveness in allergic mice by rolipram: involvement of endogenously released corticosterone and catecholamines. ( Chapman, RW; Crawley, Y; Kreutner, W; Kung, TT; Luo, B; Young, S, 2000) |
| "Administration of propranolol can provoke bronchoconstriction in asthmatic patients." | 3.69 | Role of sensory neuropeptides in post-allergic propranolol-induced bronchoconstriction in guinea pigs in vivo. ( Fujimura, M; Ishiura, Y; Matsuda, T; Myou, S; Tsujiura, M, 1996) |
| "The anti-asthmatic effects of CS-518 (sodium 2-(1-imidazolylmethyl)-4,5-dihydrobenzo[b]thiophene-6-carboxylate) , a specific thromboxane A2 (TXA2) synthase inhibitor, were investigated in the ovalbumin-sensitized guinea pig asthmatic model." | 3.68 | Effects of CS-518, a thromboxane synthase inhibitor, on the asthmatic response. ( Iizuka, Y; Itoh, K; Mukaiyama, O; Satoh, Y; Terada, A; Yamaguchi, T, 1993) |
| "Inhaled propranolol (P) was administered to a population which included asthmatic children (30 subjects) and adults (43 subjects): 1) to investigate the determinants of induced bronchial response; 2) to examine the relationship with treatment requirements; 3) to determine the relationship with responsiveness to methacholine (M) and ultrasonically nebulized distilled water (UNDW) (50 subjects); and 4) to establish the short-term repeatability of bronchial response to propranolol compared with methacholine (22 subjects)." | 3.68 | Bronchial responsiveness to inhaled propranolol in asthmatic children and adults. ( Chetta, A; Foresi, A; Mastropasqua, B; Moretti, D; Olivieri, D; Pelucchi, A, 1993) |
| " The provocation dose at a decrease in sGaw of 50% (PD50) was calculated from the dose-response curve." | 2.67 | [Comparison of the characteristics of methacholine and of propranolol in the assessment of aspecific hyperreactivity of the airways]. ( Laxy, T; Schultze-Werninghaus, G; Siekmeier, R, 1991) |
| "Propranolol appears to be an effective treatment option for IH even in the nonproliferative phase and after the first year of life." | 1.37 | Adverse effects of propranolol when used in the treatment of hemangiomas: a case series of 28 infants. ( Breugem, CC; Breur, JMPJ; de Graaf, M; Pasmans, SGMA; Raphaël, MF; Vos, M, 2011) |
| " In contrast, the dose-response curve for substance P recorded 1 h after antigen challenge was not modified by pretreatment with silymarin." | 1.31 | Protective effect of silymarin in antigen challenge- and histamine-induced bronchoconstriction in in vivo guinea-pigs. ( Apostoliti, F; Breschi, MC; Martinotti, E; Nieri, P, 2002) |
| "Propranolol was inhaled 20 minutes after an antigen challenge in passively sensitized, anesthetized, and artificially ventilated guinea pigs." | 1.30 | Difference in bronchoprotective effects of bronchodilators on postallergic propranolol-induced bronchoconstriction. ( Fujimura, M; Ishiura, Y; Matsuda, T; Mizuhashi, K; Myou, S, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (57.14) | 18.2507 |
| 2000's | 6 (28.57) | 29.6817 |
| 2010's | 3 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tohda, Y | 1 |
| de Graaf, M | 1 |
| Breur, JMPJ | 1 |
| Raphaël, MF | 1 |
| Vos, M | 1 |
| Breugem, CC | 1 |
| Pasmans, SGMA | 1 |
| Jian, D | 1 |
| Chen, X | 1 |
| Babajee, K | 1 |
| Su, J | 1 |
| Li, J | 2 |
| Hu, X | 1 |
| Xie, H | 1 |
| Boskabady, MH | 1 |
| Zarei, A | 1 |
| Mirić, M | 1 |
| Plavec, D | 1 |
| van der Woude, HJ | 1 |
| Zaagsma, J | 1 |
| Postma, DS | 2 |
| Winter, TH | 1 |
| van Hulst, M | 1 |
| Aalbers, R | 1 |
| Howell, RE | 1 |
| Kovalsky, MP | 1 |
| Laemont, KD | 1 |
| Jarreau, PH | 1 |
| D'Ortho, MP | 1 |
| Boyer, V | 1 |
| Harf, A | 1 |
| Macquin-Mavier, I | 1 |
| Yamaguchi, T | 1 |
| Mukaiyama, O | 1 |
| Itoh, K | 1 |
| Satoh, Y | 1 |
| Terada, A | 1 |
| Iizuka, Y | 1 |
| Tang, CB | 1 |
| Quan, BW | 1 |
| Wang, XF | 1 |
| Xiong, YX | 1 |
| Wu, GH | 1 |
| Oosterhoff, Y | 1 |
| Koëter, GH | 1 |
| De Monchy, JG | 1 |
| Foresi, A | 1 |
| Chetta, A | 1 |
| Pelucchi, A | 1 |
| Mastropasqua, B | 1 |
| Moretti, D | 1 |
| Olivieri, D | 1 |
| Fujimura, M | 2 |
| Tsujiura, M | 1 |
| Myou, S | 2 |
| Ishiura, Y | 2 |
| Matsuda, T | 2 |
| Seeds, EA | 1 |
| Spina, D | 1 |
| Page, CP | 1 |
| Mizuhashi, K | 1 |
| Kung, TT | 1 |
| Crawley, Y | 1 |
| Luo, B | 1 |
| Young, S | 1 |
| Kreutner, W | 1 |
| Chapman, RW | 1 |
| Van Schoor, J | 1 |
| Joos, GF | 1 |
| Pauwels, RA | 1 |
| Breschi, MC | 1 |
| Martinotti, E | 1 |
| Apostoliti, F | 1 |
| Nieri, P | 1 |
| Sasaki, F | 1 |
| Ishizaki, T | 1 |
| Takahashi, H | 1 |
| Ameshima, S | 1 |
| Nakai, T | 1 |
| Miyabo, S | 1 |
| Iwama, T | 1 |
| Shikada, K | 1 |
| Yamamoto, A | 1 |
| Sakashita, M | 1 |
| Hibi, M | 1 |
| Tanaka, S | 1 |
| Schultze-Werninghaus, G | 1 |
| Siekmeier, R | 1 |
| Laxy, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 2 Study of Sildenafil for the Treatment of Lymphatic Malformations[NCT02335242] | Phase 2 | 22 participants (Actual) | Interventional | 2015-05-23 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Participants will be followed for the duration of the study, an expected average of 20 weeks. (NCT02335242)
Timeframe: Baseline, week 20
| Intervention | percentage of volume (Mean) |
|---|---|
| Double-Blind Placebo | 5.89 |
| Open-Label Sildenafil | -8.54 |
| Double-blind Sildenafil | -0.642 |
"Subject's evaluation of the overall change in lymphatic malformation. Participants will be followed from baseline to 20 weeks.~Patients rated change as no improvement, minimal improvement (1-25% change), fair improvement (25-50% change), good improvement (50-75% change), and excellent improvement (75-100% change)." (NCT02335242)
Timeframe: Baseline, week 20
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| No improvement | Minimal improvement | Fair improvement | Good improvement | Excellent improvement | |
| Double-Blind Placebo | 1 | 2 | 0 | 2 | 0 |
| Double-Blind Sildenafil | 2 | 4 | 1 | 1 | 0 |
2 reviews available for propranolol and Bronchial Hyperreactivity
| Article | Year |
|---|---|
[My research on asthma today and in the future].
Topics: Adrenergic beta-Antagonists; Animals; Anti-Inflammatory Agents; Asthma; Bronchial Hyperreactivity; D | 2013 |
Indirect bronchial hyperresponsiveness in asthma: mechanisms, pharmacology and implications for clinical research.
Topics: Adenosine; Adenosine Monophosphate; Adrenergic beta-Antagonists; Aerosols; Asthma; Bradykinin; Bronc | 2000 |
3 trials available for propranolol and Bronchial Hyperreactivity
| Article | Year |
|---|---|
Risk of acute bronchospasm and bronchial hyperreactivity from inhaled acid aerosol in healthy subjects: randomized, double-blind controlled trial.
Topics: Adrenergic beta-Antagonists; Adult; Aerosols; Analysis of Variance; Bronchial Hyperreactivity; Bronc | 2004 |
Detrimental effects of beta-blockers in COPD: a concern for nonselective beta-blockers.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Adult; Aged; Bronchial Hyperreactivity; Bronc | 2005 |
[Comparison of the characteristics of methacholine and of propranolol in the assessment of aspecific hyperreactivity of the airways].
Topics: Adolescent; Adult; Bronchial Hyperreactivity; Bronchial Provocation Tests; Dose-Response Relationshi | 1991 |
16 other studies available for propranolol and Bronchial Hyperreactivity
| Article | Year |
|---|---|
Adverse effects of propranolol when used in the treatment of hemangiomas: a case series of 28 infants.
Topics: Adrenergic beta-Antagonists; Biopsy, Needle; Bronchial Hyperreactivity; Cohort Studies; Dose-Respons | 2011 |
Adverse effects of propranolol treatment for infantile hemangiomas in China.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Bronchial Hyperreactivity; China; Female; Hemangi | 2014 |
Increased tracheal responsiveness to beta-adrenergic agonist and antagonist in ovalbumin-sensitized guinea pigs.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Aerosols; Animals | 2004 |
Methoctramine induces nonspecific airway hyperresponsiveness in vivo.
Topics: Aerosols; Albuterol; Animals; Arachidonic Acid; Atropine; Bronchial Hyperreactivity; Bronchoconstric | 1994 |
Effects of capsaicin on the airway responses to inhaled endotoxin in the guinea pig.
Topics: Administration, Inhalation; Airway Resistance; Analysis of Variance; Animals; Bronchial Hyperreactiv | 1994 |
Effects of CS-518, a thromboxane synthase inhibitor, on the asthmatic response.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Asthma; Bronchial Hyper | 1993 |
Influence of airway inflammatory changes on airway hyperresponsiveness in asthmatics.
Topics: Adult; Albuterol; Asthma; Beclomethasone; Bronchial Hyperreactivity; Bronchial Provocation Tests; Br | 1993 |
Circadian variation in airway responsiveness to methacholine, propranolol, and AMP in atopic asthmatic subjects.
Topics: Adenosine Monophosphate; Adult; Asthma; Bronchi; Bronchial Hyperreactivity; Bronchial Provocation Te | 1993 |
Bronchial responsiveness to inhaled propranolol in asthmatic children and adults.
Topics: Administration, Inhalation; Adult; Aerosols; Asthma; Bronchial Hyperreactivity; Bronchial Provocatio | 1993 |
Role of sensory neuropeptides in post-allergic propranolol-induced bronchoconstriction in guinea pigs in vivo.
Topics: Adrenergic beta-Antagonists; Animals; Asthma; Bronchial Hyperreactivity; Bronchoconstriction; Dipept | 1996 |
The role of sensory nerves in propranolol-induced bronchial hyperresponsiveness in the guinea-pig.
Topics: Acetylcholine; Animals; Bombesin; Bradykinin; Bronchial Hyperreactivity; Capsaicin; Guinea Pigs; Mal | 1999 |
Difference in bronchoprotective effects of bronchodilators on postallergic propranolol-induced bronchoconstriction.
Topics: Airway Resistance; Albuterol; Aminophylline; Animals; Atropine; Bronchi; Bronchial Hyperreactivity; | 1999 |
Inhibition of pulmonary eosinophilia and airway hyperresponsiveness in allergic mice by rolipram: involvement of endogenously released corticosterone and catecholamines.
Topics: Animals; Antihypertensive Agents; Bronchial Hyperreactivity; Bronchoalveolar Lavage; Catecholamines; | 2000 |
Protective effect of silymarin in antigen challenge- and histamine-induced bronchoconstriction in in vivo guinea-pigs.
Topics: Animals; Bronchial Hyperreactivity; Bronchoconstriction; Guinea Pigs; Histamine; Male; Ovalbumin; Pl | 2002 |
[Bronchial hyperresponsiveness to acetylcholine during acute pulmonary congestion in guinea pigs].
Topics: Acetylcholine; Adrenergic beta-Antagonists; Airway Resistance; Animals; Bronchial Hyperreactivity; G | 1992 |
Effect of NZ-107 on late-phase airway responses and airway hyperreactivity in guinea pigs.
Topics: Aerosols; Animals; Antigens; Bronchial Hyperreactivity; Bronchoconstriction; Drug Hypersensitivity; | 1991 |